Views: 220 Downloads: 37

Abstract

This study evaluates the effectiveness of combination antiviral therapy for COVID-19 using Umifenovir and Oseltamivir compared with standard treatment. A total of 85 outpatients with confirmed COVID-19 were randomly assigned to two groups: 43 patients received combination antiviral therapy (Umifenovir 200 mg 4 times daily, Oseltamivir 75 mg twice daily for 7 days), and 42 received standard therapy based on WHO recommendations. The study spanned 16 months. Primary endpoints included the number of patients with fever, cough, sore throat, diarrhea, and the need for hospitalization or intensive care at 1, 2, and 3 weeks post-infection. The secondary endpoint was a negative PCR test at 7, 14, and 21 days.

Results showed that 72% of patients in the antiviral group and 67% in the control group had alpha and omicron variants. Patients receiving combination therapy showed a significantly faster resolution of fever and cough within the first two weeks. Viral elimination by the end of the second week occurred in 95% of patients in the combination group, compared to 79% in the control group (P<0.05). The therapy was well-tolerated, and the combination was twice more effective in symptom relief, virus clearance, and reducing the need for hospitalization. Combination therapy with Umifenovir and Oseltamivir presents a promising treatment approach for outpatient COVID-19 cases‎.

Keywords: Treatment of COVID-19, Antiviral therapy of COVID-19, Umifenovir in the treatment of COVID-19, Oseltamivir in the treatment of COVID-19

Citation Formats: